You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Introduction

The HER2 protein is overexpressed in 20 to 30% of breast cancers, and recent advances in HER2-directed therapies have revolutionized the treatment of HER2-positive breast cancer in both the early (adjuvant) and advanced (metastatic) settings. However, the HER2 field continues to evolve with the development of various HER2-targeted therapies that will address issues such as treatment resistance, optimal treatment paradigms, and patient quality of life.

Activities

Steering Committee

Steering Committee Chair
  • Karen A. Gelmon, MDKaren A. Gelmon, MD
    Professor of Medicine,
    University of British
    Columbia Medical Oncologist,
    British Columbia Cancer Agency
    Vancouver Cancer Centre,
    Clinical Head Investigational
    Drug Program Experimental Therapeutics,
    British Columbia Cancer Research Centre,
    Vancouver, Canada
Steering Committee Members
  • Carlos H. Barrios, MDCarlos H. Barrios, MD
    Professor, Internal Medicine Department, PUCRS School of Medicine; Director, Oncology Research Unit, Pontifícia Universidade Católica, Porto Alegre, Brazil
  • Javier Cortés, MD, PhDJavier Cortés, MD, PhD
    Deputy Director, Breast Cancer Program, Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
  • Paul A. Ellis, MD, FRACPPaul A. Ellis, MD, FRACP
    Professor of Cancer Medicine, Guy's Hospital; King's College, London; Principal Investigator, Sarah Cannon Research Institute, London, United Kingdom
  • Nadia Harbeck, MD, PhDNadia Harbeck, MD, PhD
    Professor, Women's Clinic Breast Center, University of Munich, Munich, Germany
  • Joseph Gligorov, MD, PhDJoseph Gligorov, MD, PhD
    Medical Oncologist, Medical Oncology Department, Head of Cancer Coordination Center HUEP, University Cancer Institute, Sorbonne University , Paris, France
Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.
Supported by an independent educational
grant from
F. Hoffman - La Roche Ltd
Polling Question

What percentage of your patients with early breast cancer receive neoadjuvant treatment?
<10%
10%-30%
30%-50%
50%-75%
>75%

Related Resources

Downloadable Slide Kit
Clinical Articles
Related Links

Disclosures

Steering Committee
Karen A. Gelmon, MD

Karen A. Gelmon, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Roche

Carlos H. Barrios, MD

Carlos H. Barrios, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche

Javier Cortés, MD, PhD

Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene Corporation; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Novartis Pharmaceuticals Corporation; Eisai Co., Ltd.; Roche

Paul A. Ellis, MD, FRACP

Paul A. Ellis, MD, FRACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis; Pfizer Inc.; Roche; Sanofi-Aventis
Served as a speaker or a member of a speakers bureau for: Roche

Nadia Harbeck, MD, PhD

Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: GlaxoSmithKline; Roche
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Roche

Joseph Gligorov, MD, PhD

Joseph Gligorov, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche; Eisai Co., Ltd.
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: Novartis Pharmaceuticals Corporation; Roche; Eisai Co., Ltd.